Certara, Inc.

Equities

CERT

US15687V1098

Software

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
16.21 USD -4.37% Intraday chart for Certara, Inc. -12.12% -7.85%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Certara Launches Cloud Platform to Unify Scientific Software Solutions MT
Certara, Inc. Launches Cloud Platform to Further Unify Its End-To-End Scientific Software Platform CI
North American Morning Briefing : Stock Futures -2- DJ
Sector Update: Health Care Stocks Slipping Late Afternoon MT
Certara Poised to Benefit From Improving End Markets, KeyBanc Says MT
KeyBanc Upgrades Certara to Overweight From Sector Weight on Higher Conviction of Top-Line Trends, Sets $23 Price Target MT
North American Morning Briefing : Traders Await -2- DJ
Certara Shares Rise After JMP Securities Starts Coverage at Market Perform MT
JMP Securities Initiates Coverage on Certara With Market Perform Rating MT
Transcript : Certara, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:05 PM
UBS Raises Certara Price Target to $20 From $17, Maintains Neutral Rating MT
Transcript : Certara, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Certera Adjusted EPS Declines, Revenue Climbs; Shares Fall After Hours MT
Certara, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Certara, Inc. Provides Earnings Guidance for the Year 2024 CI
Certara, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (CERT) CERTARA Posts Q4 EPS $0.09, vs. Street Est of $0.11 MT
Earnings Flash (CERT) CERTARA Reports Q4 Revenue $88M, vs. Street Est of $86.7M MT
Leerink Partners Initiates Certara at Market Perform Rating With $19 Price Target MT
Barclays Adjusts Price Target on Certara to $18 From $16, Maintains Equal-Weight Rating MT
Certara Acquires Applied BioMath to Expand Biosimulation Capabilities MT
Certara, Inc. (NasdaqGS : CERT) acquired Applied BioMath, LLC for $36.6 million. CI
UBS Initiates Coverage on Certara With Neutral Rating, $17 Price Target MT
KeyBanc Initiates Certara at Sector Weight, Sees Current Valuation as 'Fair Given The More Muted End Markets' MT
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday MT
Chart Certara, Inc.
More charts
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development in the global biopharmaceutical industry. It is focused on producing medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its customers include life sciences companies of all sizes along with contract research organizations, academic institutions, and global regulators. Its software and service are used by approximately 2,400 biopharmaceutical companies and academic institutions across 66 countries, including 38 of the top 40 biopharmaceutical companies. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, Netherlands, Philippines, Poland, Portugal, Spain, Switzerland, Egypt, and the United Kingdom.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
16.95 USD
Average target price
19.74 USD
Spread / Average Target
+16.46%
Consensus